SNMMI Clinical Trials Network Research Series for Technologists: An Introduction to Conducting Theranostic Clinical Trials

• Published in: Journal of nuclear medicine technology Vol. 52; no. 3; pp. 184 - 191
• Main Authors: Gonzalez, Freddy, Scott, Peter J H, Jeffers, Charlotte Denise, Kappadath, S Cheenu
• Format: Journal Article
• Language: English
• Published: United States 05-09-2024
• Subjects: Clinical Trials as Topic; Humans; Nuclear Medicine; Precision Medicine - methods; Radiopharmaceuticals - therapeutic use; Societies, Medical; theranostics; dosimetry; infusion; technologist
• ISSN: 0091-4916; 1535-5675; 1535-5675
• DOI: 10.2967/jnmt.123.266588

This article is intended to introduce nuclear medicine technologists (NMTs) to the nuances of radiopharmaceutical therapy clinical trials. Here, we outline the potential roles and responsibilities of the NMT in clinical trials and provide context on different aspects of radionuclide therapy. The regulatory process involving investigational therapeutic radiopharmaceuticals is seldom taught to NMT students, nor is it included in the entry-level nuclear medicine certification examinations. Often, NMTs must spend significant time preparing for therapeutic clinical trials on their own, using multiple academic sources, seeking advice from various health care professionals, and reviewing numerous trial-specific manuals to recognize the detailed requirements. The emergence of theranostics has spurred an increase in the development of therapeutic radiopharmaceuticals. Investigators with a robust nuclear medicine background are required to help develop successful therapeutic clinical trials, and well-informed NMTs are crucial to the success of such trials. This article follows a series of previous publications from the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network research series for technologists and is intended to guide the investigational radiopharmaceutical landscape.